Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
Urology|February 22, 2011
Phase II evaluation of early oral estramustine, oral etoposide, and intravenous paclitaxel combined with hormonal therapy in patients with high-risk metastatic prostate adenocarcinoma: Southwest Oncology Group S0032David C Smith, Cathy M Tangen, Peter J Van Veldhuizen, et al.
JAMA Network Open|August 1, 2023
Race and Treatment Outcomes in Patients With Metastatic Castration-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG 1216 Phase 3 TrialNicolas Sayegh, Umang Swami, Yeonjung Jo, et al.
European Urology|December 12, 2018
Inflammatory Bowel Disease and the Risk of Prostate CancerJacob A Burns, Adam B Weiner, William J Catalona, et al.
Cancer|April 3, 2008
Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426)A Oliver Sartor, Catherine M Tangen, Maha H A Hussain, et al.
Therapeutic Advances in Medical Oncology|November 19, 2010
COOPERATIVE GROUP TRIALS - SOUTHWEST ONCOLOGY GROUP (SWOG) INNOVATIONS IN ADVANCED PROSTATE CANCERTanya B Dorff, Cathy M Tangen, E David Crawford, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 21, 2010
Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancerTanya B Dorff, Bryan Goldman, Jacek K Pinski, et al.
Clinical Genitourinary Cancer|October 1, 2008
Southwest Oncology Group phase II study of ispinesib in androgen-independent prostate cancer previously treated with taxanesTomasz M Beer, Bryan Goldman, Timothy W Synold, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2007
Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trialMaha H A Hussain, Gary R MacVicar, Daniel P Petrylak, et al.
The Journal of Urology|August 28, 2012
Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346)Catherine M Tangen, Maha H A Hussain, Celestia S Higano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2006
Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone, Donna L Berry, Carol M Moinpour, et al.
Pageof 5